5:28 PM
 | 
Oct 02, 2008
 |  BC Extra  |  Top Story

Merck dropping taranabant for obesity

Merck (NYSE:MRK) said it ended development of taranabant (formerly MK-0364) to treat obesity after pooled data from a Phase III program showed "efficacy and adverse events were dose related, with greater efficacy and more adverse events in the higher doses."...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >